Literature DB >> 30236840

Mucus-penetrating budesonide nanosuspension enema for local treatment of inflammatory bowel disease.

Abhijit A Date1, Gilad Halpert1, Taarika Babu2, Jairo Ortiz1, Pranjali Kanvinde3, Peter Dimitrion3, Janani Narayan4, Hannah Zierden4, Kalpana Betageri5, Olivia Musmanno5, Helen Wiegand5, Xinglu Huang1, Sanjeev Gumber6, Justin Hanes7, Laura M Ensign8.   

Abstract

Inflammatory bowel disease (IBD) is a chronic inflammatory gastrointestinal disorder that affects more than 1 million individuals in the USA. Local therapy with enema formulations, such as micronized budesonide (Entocort®), is a common strategy for treating patients with distally active IBD. However, we hypothesize that micronized particulates are too large to effectively penetrate colorectal mucus, limiting the extent of drug delivery to affected tissues prior to clearance. Here, we describe the development of a budesonide nanosuspension (NS) with the appropriate surface coating and size to enhance penetration of colorectal mucus and ulcerated colorectal tissues. We demonstrate that model fluorescent polystyrene (PS) particles ∼200 nm in size with a muco-inert Pluronic F127 coating provide enhanced mucosal distribution and tissue penetration in mice with trinitrobenzenesulfonic acid (TNBS)-induced IBD compared to model 2 μm PS particles coated with polyvinylpyrollidone (PVP), the stabilizer used in the clinical micronized budesonide formulation. We then used a wet-milling process to develop a budesonide NS formulation with a muco-inert Pluronic F127 coating (particle size ∼230 nm), as well as a budesonide microsuspension (MS) stabilized with PVP (particle size ∼2 μm). Using an acute TNBS mouse model of IBD, we show that daily budesonide NS enema treatment resulted in a significant reduction in the macroscopic (decreased colon weight) and microscopic (histology score) symptoms of IBD compared to untreated controls or mice treated daily with the budesonide MS enema. Further, we show that the budesonide NS enema treated mice had a significantly reduced number of inflammatory macrophages and IL-β producing CD11b + cells in colon tissue compared to untreated controls or mice treated with the budesonide MS enema. We conclude that the nano-size and muco-inert coating allowed for enhanced local delivery of budesonide, and thus, a more significant impact on local colorectal tissue inflammation.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Budesonide; Colitis; Pluronic F127; Trinitrobenzenesulfonic acid (TNBS); Wet-milling

Mesh:

Substances:

Year:  2018        PMID: 30236840      PMCID: PMC6193453          DOI: 10.1016/j.biomaterials.2018.09.005

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  48 in total

1.  Rectal pharmacokinetics of budesonide.

Authors:  K Dahlstrom; S Edsbacker; A Kallen
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

Review 2.  The role of the glucocorticoid receptor in inflammation and immunity.

Authors:  Ulrike Baschant; Jan Tuckermann
Journal:  J Steroid Biochem Mol Biol       Date:  2010-03-24       Impact factor: 4.292

3.  Ly6C hi monocytes in the inflamed colon give rise to proinflammatory effector cells and migratory antigen-presenting cells.

Authors:  Ehud Zigmond; Chen Varol; Julia Farache; Elinor Elmaliah; Ansuman T Satpathy; Gilgi Friedlander; Matthias Mack; Nahum Shpigel; Ivo G Boneca; Kenneth M Murphy; Guy Shakhar; Zamir Halpern; Steffen Jung
Journal:  Immunity       Date:  2012-12-06       Impact factor: 31.745

Review 4.  [Immunopathogenesis of inflammatory bowel disease].

Authors:  Julien Matricon
Journal:  Med Sci (Paris)       Date:  2010-04       Impact factor: 0.818

5.  Ex vivo characterization of particle transport in mucus secretions coating freshly excised mucosal tissues.

Authors:  Laura M Ensign; Andreas Henning; Craig S Schneider; Katharina Maisel; Ying-Ying Wang; Marc D Porosoff; Richard Cone; Justin Hanes
Journal:  Mol Pharm       Date:  2013-05-23       Impact factor: 4.939

6.  Fluticasone and budesonide nanosuspensions for pulmonary delivery: preparation, characterization, and pharmacokinetic studies.

Authors:  Jerry Z Yang; Anthony L Young; Po-Chang Chiang; Archie Thurston; Denise K Pretzer
Journal:  J Pharm Sci       Date:  2008-11       Impact factor: 3.534

7.  Nano- and microscaled particles for drug targeting to inflamed intestinal mucosa: a first in vivo study in human patients.

Authors:  Carsten Schmidt; Christian Lautenschlaeger; Eva-Maria Collnot; Michael Schumann; Christian Bojarski; Jörg-Dieter Schulzke; Claus-Michael Lehr; Andreas Stallmach
Journal:  J Control Release       Date:  2012-11-02       Impact factor: 9.776

8.  Enhanced vaginal drug delivery through the use of hypotonic formulations that induce fluid uptake.

Authors:  Laura M Ensign; Timothy E Hoen; Katharina Maisel; Richard A Cone; Justin S Hanes
Journal:  Biomaterials       Date:  2013-06-13       Impact factor: 12.479

9.  An in vivo comparison of intestinal pH and bacteria as physiological trigger mechanisms for colonic targeting in man.

Authors:  Emma L McConnell; Michael D Short; Abdul W Basit
Journal:  J Control Release       Date:  2008-07-18       Impact factor: 9.776

Review 10.  Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue.

Authors:  Susan Hua; Ellen Marks; Jennifer J Schneider; Simon Keely
Journal:  Nanomedicine       Date:  2015-03-14       Impact factor: 5.307

View more
  12 in total

Review 1.  Chronic Inflammatory Diseases, Anti-Inflammatory Agents and Their Delivery Nanosystems.

Authors:  Daniela Placha; Josef Jampilek
Journal:  Pharmaceutics       Date:  2021-01-06       Impact factor: 6.321

Review 2.  Sticking to the Problem: Engineering Adhesion in Molecular Endoscopic Imaging.

Authors:  Mahboubeh S Noori; Sarah J Bodle; Christian A Showalter; Evan S Streator; David S Drozek; Monica M Burdick; Douglas J Goetz
Journal:  Cell Mol Bioeng       Date:  2020-01-21       Impact factor: 2.321

3.  Development of a mucoinert progesterone nanosuspension for safer and more effective prevention of preterm birth.

Authors:  Thuy Hoang; Hannah Zierden; Abhijit Date; Jairo Ortiz; Sanjeev Gumber; Nicole Anders; Ping He; James Segars; Justin Hanes; Mala Mahendroo; Laura M Ensign
Journal:  J Control Release       Date:  2018-12-28       Impact factor: 9.776

4.  Enhanced drug delivery to the reproductive tract using nanomedicine reveals therapeutic options for prevention of preterm birth.

Authors:  Hannah C Zierden; Jairo I Ortiz; Kevin DeLong; Jingqi Yu; Gaoshan Li; Peter Dimitrion; Sabrine Bensouda; Victoria Laney; Anna Bailey; Nicole M Anders; Morgan Scardina; Mala Mahendroo; Sam Mesiano; Irina Burd; Gunter Wagner; Justin Hanes; Laura M Ensign
Journal:  Sci Transl Med       Date:  2021-01-13       Impact factor: 17.956

Review 5.  Avoiding a Sticky Situation: Bypassing the Mucus Barrier for Improved Local Drug Delivery.

Authors:  Hannah C Zierden; Aditya Josyula; Rachel L Shapiro; Henry T Hsueh; Justin Hanes; Laura M Ensign
Journal:  Trends Mol Med       Date:  2021-01-04       Impact factor: 11.951

Review 6.  Advanced modification of drug nanocrystals by using novel fabrication and downstream approaches for tailor-made drug delivery.

Authors:  Tao Liu; Xinxin Yu; Haipeng Yin; Jan P Möschwitzer
Journal:  Drug Deliv       Date:  2019-12       Impact factor: 6.419

Review 7.  Interactions between Nanoparticles and Intestine.

Authors:  Manuela Vitulo; Elisa Gnodi; Raffaella Meneveri; Donatella Barisani
Journal:  Int J Mol Sci       Date:  2022-04-14       Impact factor: 6.208

8.  Induction of the integrated stress response in the rat cornea.

Authors:  C Peterson; Y C Kim; L M Ensign; A S Jun; J Foster
Journal:  Exp Eye Res       Date:  2021-08-08       Impact factor: 3.770

Review 9.  Emerging role of nanosuspensions in drug delivery systems.

Authors:  Shery Jacob; Anroop B Nair; Jigar Shah
Journal:  Biomater Res       Date:  2020-01-15

10.  To Enhance Mucus Penetration and Lung Absorption of Drug by Inhalable Nanocrystals-In-Microparticles.

Authors:  Guiting Huang; Shuyuan Shuai; Weicheng Zhou; Yingchong Chen; Baode Shen; Pengfei Yue
Journal:  Pharmaceutics       Date:  2022-02-28       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.